Track topics on Twitter Track topics that are important to you
NEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Celladon Corporation (NASDAQ:CLDN) securities between July 7, 2014 and June 25, 2015.
Click here to learn about the case: http://docs.wongesq.com/CLDN-Info-Request-Form-839. There is no cost or obligation to you.
The complaint alleges that during the Class Period defendants made false and misleading statements and/or failed to disclose adverse information regarding the Company's prospects for its lead drug candidate, MYDICAR, for treating enzyme deficiency in heart failure patients that results in inadequate pumping of the heart.
On April 26, 2015, Celladon announced that the Company's Phase 2b CUPID2 trial of MYDICAR did not meet its primary and secondary goals. Then on June 1, 2015, Celladon issued a press release announcing the abrupt resignation of the Company's Chief Executive Officer. Then, on June 26, 2015, Celladon announced the suspension of its plans for further research or development of its MYDICAR program and other pre-clinical programs, indicating there was a possibility that the Company could be liquidated with net cash available to shareholders of $25-$30 million.
If you suffered a loss in Celladon you have until August 31, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://docs.wongesq.com/CLDN-Info-Request-Form-839.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: email@example.comNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...